Recon: Marks says Kennedy’s team sought ‘nonexistent’ data on vaccines; Novo to invest $1.09B to increase Ozempic, Wegovy production in Brazil
Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.In Focus: US
- Trump layoffs begin to erode FDA drug review system (Reuters)
- Ousted Vaccine Chief Says RFK Jr.’s Team Sought Data to Justify Anti-Science Stance (WSJ)
- ‘Most effective way’ to prevent measles is vaccination, RFK Jr. says, in most direct remarks yet (STAT)
- School-age child dies in Texas measles outbreak; health chief Kennedy visits family (Reuters)
- U.S. may be reverting to a time when measles deaths were not very rare, experts warn (STAT)
- BridgeBio CEO: Congress must renew a popular, bipartisan FDA program benefiting sick kids (STAT)
- Trump administration drops Biden's proposal of Medicare weight-loss drug coverage (Reuters)
- FTC eyes resuming insulin lawsuit against drug middlemen (Reuters)
- Novo Nordisk to invest $1.09 billion to boost Ozempic, Wegovy production in Brazil (Reuters)
- Small-town Ireland nervous as Trump seeks to lure pharma investment to US (Reuters)
- Britain to invest up to $767 mln in new health data research (Reuters)
- Mexico reports first human case of H5N1 bird flu (Reuters)
- UK's Assura gets deadline extension for potential PHP deal (Reuters)
- Aid cuts could leave more women dying in pregnancy and birth, UN says (Reuters)
- A brash biotech VC speaks out on headwinds in the industry, and what the future may hold (STAT)
- Rhythm touts Phase 3 win for rare obesity drug in people with brain damage (Endpoints)
- Cell and gene therapy CDMO AmplifyBio shuts down over 'scarcity' of funding (Endpoints)
- Sarepta halts three studies testing gene therapy for muscle disorder (Reuters)
- Q&A: A conversation with GLP-1 co-discoverer Jens Juul Holst on the future of incretin-based drugs (Endpoints)
- Q&A: David Liu talks about science under pressure, teases “disease-agnostic” gene editing (Endpoints)
- ADC startup DualityBio seeks Hong Kong IPO amid precarious market (Endpoints)
- GSK’s newest neuro pact is with ABL Bio, a Sanofi-partnered South Korean biotech (Endpoints)
- New thought-to-speech brain device allows for ‘natural conversation’ (STAT)
- A ‘wobbly’ moment in business: Manufacturers face life under Trump’s tariffs (MedTech Dive)
- Labcorp launches blood test to accelerate Alzheimer’s diagnosis (MedTech Dive)
- Pushing On An Open EU Door? Time For MHRA To Get Practical About UK’s Regulatory Ambition (MedTech Insight)
- Texas opens probe into WK Kellogg over health claims (Reuters)
- Quality, SQF, and the Importance of Changing Food Safety Behaviors (Food Safety)
- FDA’s Vape Ban Hits the Right Note: Supreme Court Says “Let It Be” (FDA Law Blog)
- Don’t overlook the continued threat of cuts to universities’ indirect research costs (STAT)
- HIV prevention was making great strides. Then Trump’s budget axe fell (STAT)
- DOJ urges judge to move forward with Medicare Advantage fraud case against UnitedHealth (STAT)
- Medicare gets a big (unofficial) surprise: a 17-year extension on when it’ll run dry (STAT)
- CDC’s top laboratory on sexually transmitted diseases is shut by Trump administration (STAT)
- Bayer renews bid for US Supreme Court to curb glyphosate cases (Reuters)
A story’s inclusion in Regulatory Recon does not imply endorsement by Regulatory Focus or RAPS.
